Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine

23 October 2020 - Canadian government to provide $173M in funding for vaccine research and development, and domestic manufacturing capacity. ...

Read more →

Health Canada has approved Taltz (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis

19 October 2020 - Taltz is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA. ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma

15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...

Read more →

Health Canada approves first-ever gene replacement therapy, Luxturna

15 October 2020 - Luxturna (voretigene neparvovec), is the first approved therapy for previously untreatable inherited retinal disease. ...

Read more →

Moderna announces initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19 (mRNA-1273)

13 October 2020 - Confirmation underscores Moderna’s commitment to make its vaccine available in Canada. ...

Read more →

Health Canada approves Inqovi (decitabine and cedazuridine) oral therapy for two types of blood cancers, MDS and CMML

8 October 2020 - Oral drug can be taken at home, which may enable some patients to avoid some hospital visits. ...

Read more →

Pfizer Canada and BioNTech initiate rolling submission to Health Canada for SARS-CoV-2 vaccine candidate BNT162b2

9 October 2020 - Pfizer Canada and BioNTech will continue regular and open dialogue with Health Canada providing results from their ...

Read more →

Health Canada approves Zeposia, an oral treatment for relapsing remitting multiple sclerosis

7 October 2020 - Bristol Myers Squibb's medication provides a new oral treatment option for Canadians living with the neurological disease. ...

Read more →

Fibristal (ulipristal acetate 5 mg tablets) voluntary withdrawal in Canada due to risk of drug-induced liver injury

30 September 2020 - Allergan is working closely with Health Canada to voluntarily withdraw Fibristal (ulipristal acetate 5 mg tablets) ...

Read more →

Health Canada approves Reblozyl (luspatercept), new class of treatment for adult patients living with beta thalassaemia

29 September 2020 - Reblozyl is the first and only erythroid maturation agent approved for use in Canada. ...

Read more →

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

22 September 2020 - Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant. ...

Read more →

Health Canada approves Inrebic (fedratinib), first new treatment in nearly a decade for patients living with myelofibrosis

21 September 2020 - Inrebic provides new, once-daily oral option for patients affected by rare bone marrow cancer. ...

Read more →

Knight and TherapeuticsMD announce Health Canada approval of Bijuva

21 September 2020 -  Knight Therapeutics and TherapeuticsMD announced today the approval of Bijuva (estradiol and progesterone) capsules by Health ...

Read more →

Brenzys (etanercept injection) now indicated for the treatment of plaque psoriasis, psoriatic arthritis and juvenile idiopathic arthritis

15 September 2020 - Brenzys is a biosimilar biologic drug authorised based on its similarity to Enbrel, which is already approved ...

Read more →

Health Canada approves Tremfya (guselkumab injection), a first in class, selective interleukin 23 inhibitor for active psoriatic arthritis

10 September 2020 - Data show Tremfya significantly improved signs and symptoms in joints, skin, and soft tissue of adults with ...

Read more →